<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975022</url>
  </required_header>
  <id_info>
    <org_study_id>12013-P-01</org_study_id>
    <nct_id>NCT04975022</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Bioavailability of Oral Insulin (N11005)</brief_title>
  <official_title>Research on Clinical Application of New Therapies for Diabetes and Its Complications and Related Translational Medicine Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to preliminarily verify whether the oral insulin N11005 is a&#xD;
      prandial insulin by assessing the PK, PD, and safety profiles of N11005.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Actual">August 14, 2020</completion_date>
  <primary_completion_date type="Actual">August 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 minutes；</time_frame>
    <description>the peak concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-8 h</measure>
    <time_frame>Pre-dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 minutes；</time_frame>
    <description>the AUC for insulin from time zero to 8 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCGIR,0-8 h</measure>
    <time_frame>Pre-dose, 0-8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GIRmax</measure>
    <time_frame>Pre-dose, 0-8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Pre-dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300,330,360,420,480 minutes；</time_frame>
    <description>time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-2 h</measure>
    <time_frame>Pre-dose, 5,10,20,30,40,50,60,75,90,105,120 minutes</time_frame>
    <description>the AUC for insulin from time zero to 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the elimination half-life (t1/2) of serum insulin</measure>
    <time_frame>Pre-dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 minutes；</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the AUC for insulin from time zero to 4 h</measure>
    <time_frame>Pre-dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the AUC for insulin from time zero to infinite time</measure>
    <time_frame>Pre-dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 minutes；</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR，0-2 h</measure>
    <time_frame>Pre-dose, 0-2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR，0-4 h</measure>
    <time_frame>Pre-dose, 0-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIRmax</measure>
    <time_frame>Pre-dose, 0-8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>PK, PD, and Safety</condition>
  <arm_group>
    <arm_group_label>T group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>R group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N11005</intervention_name>
    <description>oral insulin N11005, 300IU, p.o.</description>
    <arm_group_label>T group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novolin R</intervention_name>
    <description>reference preparation Novolin R, 0.1 IU/Kg, i.h.</description>
    <arm_group_label>R group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Volunteer to participate in the trial and sign an informed consent form; 2) 18-45&#xD;
             years old (including 18 and 45 years old) healthy male subjects (without heart, liver,&#xD;
             kidney, digestive tract, neurological diseases, and metabolic abnormalities in the 4&#xD;
             weeks before screening; No abnormal clinically significant vital signs results,&#xD;
             physical examination results, laboratory examination results and electrocardiogram&#xD;
             examination results judged by the investigator at the time of screening); 3) BMI (body&#xD;
             mass index): between 19-24 Kg/m2, including 19 and 24 Kg/m2; 4) Normal glucose&#xD;
             tolerance (fasting plasma glucose [FPG] &lt;6.1 mmol/L, and oral glucose tolerance test&#xD;
             [OGTT] 2-hour postprandial blood glucose &lt;7.8 mmol/L); 5) No family history of&#xD;
             diabetes, obesity, etc.; 6) Insulin secretion function is normal (confirmed by insulin&#xD;
             release test (IRT) judged by the investigator); 7) There is no planned parenthood&#xD;
             during the study period, and it is agreed to use reliable contraceptive measures&#xD;
             during the study period until 4 weeks after the last administration of the study drug;&#xD;
             8) Be able to communicate well with researchers and complete research in accordance&#xD;
             with research regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1). Those who have serious systemic diseases, infectious diseases or mental disorders;&#xD;
             2). The results of human immunodeficiency virus (HIV) antibody, hepatitis B surface&#xD;
             antigen (HBsAg) or hepatitis C virus (HCV) antibody, syphilis test are positive; 3).&#xD;
             Those who have used any prescription drugs, Chinese herbal medicines and/or&#xD;
             over-the-counter drugs (except for subjects with occasional and restricted use of&#xD;
             paracetamol) and health products (except routine vitamin supplements) within 2 weeks&#xD;
             before screening; 4). Those who donated more than 400 mL of blood within 3 months&#xD;
             before screening; 5). Severe smokers (25 or more cigarettes per day); 6). Alcoholics&#xD;
             (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits,&#xD;
             or 100 mL of wine), or those who have a positive alcohol breath test result; 7). Those&#xD;
             who have a history of drug abuse or have a positive urine test for illegal drugs; 8).&#xD;
             Those who are known or suspected to be allergic to insulin and/or its excipients; 9).&#xD;
             Those who have participated in other clinical trials within 3 months before screening,&#xD;
             or plan to participate in other clinical trials during the trial period or within 1&#xD;
             month after the end of the trial; 10). Those who have any food allergies or have&#xD;
             special dietary requirements and cannot follow a unified diet; 11). Those who have&#xD;
             undergone gastrointestinal surgery before screening, or have a history of gastric&#xD;
             obstruction or impaired gastrointestinal motility; 12). Those who are using gastric&#xD;
             mucosal protective agents during screening; 13). Those who are deemed unsuitable to&#xD;
             participate in this trial after the researcher's evaluation;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

